Tandem Diabetes Care, Inc. (TNDM)

$35.56

+0.44

(+1.25%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Tandem Diabetes Care, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 185.62M → 196.79M (in $), with an average increase of 5.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -123.87M → -30.00M (in $), with an average increase of 88.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 43.4% return, outperforming this stock by 48.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 73.3% return, outperforming this stock by 135.9%

Performance

  • $34.97
    $36.17
    $35.56
    downward going graph

    1.66%

    Downside

    Day's Volatility :3.32%

    Upside

    1.69%

    downward going graph
  • $13.82
    $40.74
    $35.56
    downward going graph

    61.14%

    Downside

    52 Weeks Volatility :66.08%

    Upside

    12.71%

    downward going graph

Returns

PeriodTandem Diabetes Care, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
55.22%
0.5%
0.0%
6 Months
97.78%
11.7%
0.0%
1 Year
-5.17%
6.2%
2.2%
3 Years
-62.56%
13.5%
-23.0%

Highlights

Market Capitalization
2.3B
Book Value
$4.78
Earnings Per Share (EPS)
-3.43
PEG Ratio
0.0
Wall Street Target Price
36.14
Profit Margin
-29.77%
Operating Margin TTM
-17.81%
Return On Assets TTM
-9.63%
Return On Equity TTM
-59.08%
Revenue TTM
747.7M
Revenue Per Share TTM
11.51
Quarterly Revenue Growth YOY
-10.8%
Gross Profit TTM
413.0M
EBITDA
-138.7M
Diluted Eps TTM
-3.43
Quarterly Earnings Growth YOY
-0.37
EPS Estimate Current Year
-1.59
EPS Estimate Next Year
-1.09
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    54%Buy
    41%Hold
    4%Sell
Based on 24 Wall street analysts offering stock ratings for Tandem Diabetes Care, Inc.(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
14
Hold
10
9
8
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 1.63%

Current $35.56
Target $36.14

Company Financials

FY18Y/Y Change
Revenue
183.9M
↑ 70.88%
Net Income
-122.6M
↑ 67.88%
Net Profit Margin
-66.68%
↑ 1.19%
FY19Y/Y Change
Revenue
362.3M
↑ 97.05%
Net Income
-24.8M
↓ 79.81%
Net Profit Margin
-6.83%
↑ 59.85%
FY20Y/Y Change
Revenue
498.8M
↑ 37.68%
Net Income
-34.4M
↑ 38.9%
Net Profit Margin
-6.89%
↓ 0.06%
FY21Y/Y Change
Revenue
702.8M
↑ 40.89%
Net Income
15.6M
↓ 145.27%
Net Profit Margin
2.21%
↑ 9.1%
FY22Y/Y Change
Revenue
801.2M
↑ 14.0%
Net Income
-94.6M
↓ 707.7%
Net Profit Margin
-11.81%
↓ 14.02%
FY23Y/Y Change
Revenue
747.7M
↓ 6.68%
Net Income
-222.6M
↑ 135.33%
Net Profit Margin
-29.77%
↓ 17.96%
Q3 FY22Q/Q Change
Revenue
204.5M
↑ 2.14%
Net Income
-49.0M
↑ 225.25%
Net Profit Margin
-23.94%
↓ 16.42%
Q4 FY22Q/Q Change
Revenue
220.5M
↑ 7.8%
Net Income
-15.9M
↓ 67.63%
Net Profit Margin
-7.19%
↑ 16.75%
Q1 FY23Q/Q Change
Revenue
169.4M
↓ 23.18%
Net Income
-123.9M
↑ 681.43%
Net Profit Margin
-73.13%
↓ 65.94%
Q2 FY23Q/Q Change
Revenue
195.9M
↑ 15.67%
Net Income
-35.8M
↓ 71.12%
Net Profit Margin
-18.26%
↑ 54.87%
Q3 FY23Q/Q Change
Revenue
185.6M
↓ 5.25%
Net Income
-33.0M
↓ 7.87%
Net Profit Margin
-17.76%
↑ 0.5%
Q4 FY23Q/Q Change
Revenue
196.8M
↑ 6.02%
Net Income
-30.0M
↓ 8.98%
Net Profit Margin
-15.25%
↑ 2.51%
FY18Y/Y Change
Total Assets
206.3M
↑ 116.36%
Total Liabilities
75.0M
↓ 39.74%
FY19Y/Y Change
Total Assets
326.1M
↑ 58.08%
Total Liabilities
131.1M
↑ 74.8%
FY20Y/Y Change
Total Assets
716.4M
↑ 119.69%
Total Liabilities
350.1M
↑ 166.99%
FY21Y/Y Change
Total Assets
905.1M
↑ 26.34%
Total Liabilities
472.0M
↑ 34.82%
FY22Y/Y Change
Total Assets
1.1B
↑ 16.31%
Total Liabilities
612.8M
↑ 29.83%
FY23Y/Y Change
Total Assets
952.7M
↓ 9.51%
Total Liabilities
639.0M
↑ 4.27%
Q3 FY22Q/Q Change
Total Assets
1.0B
↑ 1.06%
Total Liabilities
625.7M
↑ 6.59%
Q4 FY22Q/Q Change
Total Assets
1.1B
↑ 0.5%
Total Liabilities
612.8M
↓ 2.06%
Q1 FY23Q/Q Change
Total Assets
954.1M
↓ 9.37%
Total Liabilities
615.4M
↑ 0.42%
Q2 FY23Q/Q Change
Total Assets
946.7M
↓ 0.78%
Total Liabilities
617.4M
↑ 0.33%
Q3 FY23Q/Q Change
Total Assets
939.9M
↓ 0.71%
Total Liabilities
625.9M
↑ 1.37%
Q4 FY23Q/Q Change
Total Assets
952.7M
↑ 1.36%
Total Liabilities
639.0M
↑ 2.1%
FY18Y/Y Change
Operating Cash Flow
-8.3M
↓ 87.42%
Investing Cash Flow
-90.7M
↓ 3361.65%
Financing Cash Flow
117.2M
↑ 261.95%
FY19Y/Y Change
Operating Cash Flow
41.9M
↓ 603.73%
Investing Cash Flow
-57.0M
↓ 37.23%
Financing Cash Flow
24.2M
↓ 79.34%
FY20Y/Y Change
Operating Cash Flow
24.7M
↓ 41.13%
Investing Cash Flow
-296.1M
↑ 419.81%
Financing Cash Flow
314.4M
↑ 1198.95%
FY21Y/Y Change
Operating Cash Flow
111.4M
↑ 351.41%
Investing Cash Flow
-186.9M
↓ 36.88%
Financing Cash Flow
51.9M
↓ 83.48%
FY22Y/Y Change
Operating Cash Flow
50.5M
↓ 54.68%
Investing Cash Flow
33.2M
↓ 117.75%
Financing Cash Flow
16.9M
↓ 67.5%
Q3 FY22Q/Q Change
Operating Cash Flow
23.9M
↑ 246.95%
Investing Cash Flow
-14.2M
↓ 322.79%
Financing Cash Flow
-774.0K
↓ 109.61%
Q4 FY22Q/Q Change
Operating Cash Flow
5.8M
↓ 75.69%
Investing Cash Flow
35.8M
↓ 352.61%
Financing Cash Flow
6.1M
↓ 888.11%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.3M
↓ 414.88%
Investing Cash Flow
-26.3M
↓ 173.59%
Financing Cash Flow
-541.0K
↓ 108.87%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.3M
↓ 65.5%
Investing Cash Flow
5.7M
↓ 121.64%
Financing Cash Flow
3.9M
↓ 829.76%

Technicals Summary

Sell

Neutral

Buy

Tandem Diabetes Care, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
5.55%
97.78%
-5.17%
-62.56%
-43.99%
Stryker Corporation
Stryker Corporation
-3.78%
30.39%
12.83%
27.09%
79.07%
Dexcom, Inc.
Dexcom, Inc.
-1.37%
70.19%
10.47%
31.82%
344.58%
Boston Scientific Corp.
Boston Scientific Corp.
7.83%
47.17%
43.37%
73.31%
95.99%
Abbott Laboratories
Abbott Laboratories
-4.16%
13.71%
-1.74%
-12.82%
36.02%
Medtronic Plc
Medtronic Plc
-5.32%
12.62%
-11.92%
-39.09%
-9.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
473.44
NA
0.0
-1.59
-0.59
-0.1
NA
4.78
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
Buy
$2.3B
-43.99%
473.44
-29.77%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
79.07%
40.83
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
344.58%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
95.99%
68.14
11.18%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
36.02%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-9.27%
25.52
13.0%

Institutional Holdings

  • BlackRock Inc

    14.09%

  • Vanguard Group Inc

    10.70%

  • Capital World Investors

    9.73%

  • Eminence Capital LLC

    7.88%

  • FMR Inc

    4.54%

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    4.47%

Company Information

tandem diabetes care, inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. the company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. tandem manufactures and sells the t:slim x2™ insulin pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® insulin pump, the first pump designed for people with greater insulin requirements. tandem is based in san diego, california. safety information please note that this account is not intended to be used for product support or medical advice. if you are having a medical emergency, please dial 911. if you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. tandem insulin pumps are intended for the subcutan

Organization
Tandem Diabetes Care, Inc.
Employees
2400
CEO
Mr. John F. Sheridan
Industry
Health Technology

Discover More

FAQs